Abstract
In April, 2010, the Japanese Government approved the Merci retriever, an endovascular device for mechanical thrombectomy in acute ischemic stroke to be used within 8 hours after the onset of symptoms. They requested us to set requisites, announce guidelines and accomplish a 3 years complete post-marketing registration study. As of July 20, 2011, Merci was used for 689 patients. The author summarized a 90-days outcome and major adverse events in 93 cases. The complete data is almost comparable to pooled data (n=305) with Merci and Multi Merci trials. Accomplishment of the post-marketing registration study will be eagerly awaited.
